Clinical Trials Logo

Cervix Cancer clinical trials

View clinical trials related to Cervix Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06452004 Active, not recruiting - HPV Infection Clinical Trials

Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)

AI-DSS
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The research project is a component of another research project that applies the protocol of the World Health Organization for screening of cervical cancer, with testing of high-risk Human Papilloma Virus (hrHPV) as first screening. In the screen, triage and treat approach women who tested positive for hrHPV are undergoing Visual Inspection of the cervix with Acetic Acid (VIA). This procedure is applied in Uganda, India and Bangladesh. However the quality of VIA by lower-trained staff is variable because Low and Middle Income Countries face limited numbers of qualified health care professionals. Artificial intelligence (AI) might be a solution to improve consistency of VIA assessment. This research validates an AI decision support system (AI-DSS) under field conditions.

NCT ID: NCT06043947 Active, not recruiting - Breast Cancer Clinical Trials

Survival Monitoring in Russian Cancer Registries

SURVIMON
Start date: August 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.

NCT ID: NCT05102240 Active, not recruiting - Cervix Cancer Clinical Trials

Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer

Start date: February 24, 2022
Phase:
Study type: Observational

Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.

NCT ID: NCT05063916 Active, not recruiting - Cervical Cancer Clinical Trials

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single center, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.

NCT ID: NCT04357873 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

PEVOsq
Start date: October 28, 2020
Phase: Phase 2
Study type: Interventional

Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)

NCT ID: NCT04256213 Active, not recruiting - Cervix Cancer Clinical Trials

COL Immunotherapy Before Radiochimio + Ipilimumab

COLIBRI
Start date: July 2, 2020
Phase: N/A
Study type: Interventional

This is a multicenter, single arm pilot study evaluating the biological impact of "Nivolumab + Ipilimumab" in patients with cervical squamous cell carcinoma requiring RT-CT as initial therapy

NCT ID: NCT03518606 Active, not recruiting - Breast Cancer Clinical Trials

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

MOVIE
Start date: June 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study, to evaluate the safety and activity of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the treatment of advanced solid tumours.

NCT ID: NCT03239626 Active, not recruiting - Cervix Cancer Clinical Trials

Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer

Start date: August 31, 2017
Phase: N/A
Study type: Interventional

To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.

NCT ID: NCT03239613 Active, not recruiting - Cervix Cancer Clinical Trials

Postoperative Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer

Start date: August 31, 2017
Phase: N/A
Study type: Interventional

To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by concurrent chemotherapy with hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.

NCT ID: NCT01549730 Active, not recruiting - Cervix Cancer Clinical Trials

Cervix Hypoxia FAZA

Start date: May 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to look for low levels of oxygen (hypoxia) in your cervix cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how cervix cancer grows and responds to treatments like radiotherapy and chemotherapy. Doctors at Princess Margaret Hospital have measured hypoxia in over 300 patients. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.